ALNOV:EPA
Novacyt SA
0,44 €
arrow_upward
+1,38%(+0,0060) 1 d.
18. nov., 10:08:47 GMT+1 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: ALNOV…
Atvērt
0,44 €
Augsta
0,44 €
Zema
0,43 €
Tirgus kapitalizācija
31,93 milj.
Vid. apjoms
139,48 tūkst.
Apjoms
4,31 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,38 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Atvērt
0,44 €
Augsta
0,44 €
Zema
0,43 €
Tirgus kapitalizācija
31,93 milj.
Vid. apjoms
139,48 tūkst.
Apjoms
4,31 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,38 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Yahoo Finance
·
pirms 20 minūtēm
Stock market today: Dow, S&P 500, Nasdaq futures rise after Nvidia clears hurdle, Anthropic prepares to price its IPO
MarketWatch
·
pirms 36 minūtēm
The S&P 500 just broke a crucial support level. Here’s what history shows may happen now.
MarketWatch
·
pirms 54 minūtēm
Stock Market Today: Dow, S&P 500 and Nasdaq set to climb as Nvidia shares rise after boosting guidance; Anthropic expected to price IPO: live updates
TradingView
·
pirms 2 stundām
Stock Market: Will S&P 500 Open Up or Down Today?
Profils
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Par “Novacyt SA”
ĢenerāldirektorsDavid Allmond
Darbinieki228
Dibināšanas datums2006. gada 3. jūl.
Galvenais birojs-
SektorsHealth Care
Nozare-
Tīmekļa vietnenovacyt.com